Natixis Advisors LLC Grows Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Natixis Advisors LLC raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 14.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,318 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,113 shares during the quarter. Natixis Advisors LLC owned 0.07% of Supernus Pharmaceuticals worth $1,226,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Supernus Pharmaceuticals by 97.1% in the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 398 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $47,000. Innealta Capital LLC bought a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 352 shares during the period. Finally, nVerses Capital LLC bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at $72,000.

Analyst Ratings Changes

Several analysts have recently weighed in on SUPN shares. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Trading Up 0.1 %

Shares of NASDAQ SUPN opened at $36.14 on Wednesday. The stock has a market capitalization of $2.00 billion, a PE ratio of 33.78 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $39.37. The stock’s fifty day simple moving average is $33.81 and its two-hundred day simple moving average is $31.14.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.29) earnings per share. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares in the company, valued at approximately $303,236. This represents a 64.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the sale, the chief executive officer now owns 926,172 shares in the company, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.